All In MedTech

Device Trial Radar · NCT01609738

Left Ventricular Septum Pacing in Patients by Transvenous Approach Through the Inter-ventricular Septum

Left Ventricular Septum Pacing in Patients by Transvenous Approach Through the Inter-ventricular Septum - Feasibility, Long-term Lead Stability and Safety

Last checked: Nov 19, 2026Latest source record: Apr 8, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

12

Actual

Start

Nov 2012

Primary completion

Feb 2015

Study completion Feb 2015

Sponsor

Lead sponsor
Maastricht University Medical CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Medtronic Cardiac Rhythm and Heart Failure
First posted
Jun 1, 2012

More device trials from this sponsor

Design

Study type
Observational
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Cardiac pacing is the only effective treatment for symptomatic bradycardia. The right ventricular apex (RVA) has become the most frequently used ventricular pacing site. However, RVA pacing has been shown to cause left ventricular (LV) dyssynchrony wich can lead to LV dysfunction and development of heart failure. Recent studies in animals have demonstrated that pacing at the LV septum induces significantly less ventricular dyssynchrony than RVA pacing and is able to improve LV function to a similar degree as biventricular (BiV) pacing. In addition it was shown that a LV septum lead can be placed permanently by driving a lead with extended helix from the RV side through the inter-ventricular septum into the LV endocardial layer. This was shown to be a feasible and safe procedure and lead stability was shown during four months of follow-up in otherwise healthy and active canines. LV septum pacing may therefore be a good treatment alternative in patients with symptomatic bradycardia, as well as patients with an indication for cardiac resynchronization therapy (CRT). The purpose of this study is to translate the findings from preclinical studies to the clinical situation by investigating the feasibility, long-term lead stability and safety of LV septum pacing by transvenous approach through the inter-ventricular septum in patients.

Conditions

  • Left Ventricular Dysfunction
  • Cardiac Conduction Defect
  • Heart Failure
  • Sick Sinus Syndrome

Interventions

  • Left ventricular septum pacing leadDevice

    A left ventricular septum pacing lead is permanently placed by introducing a custom lead with extended helix transvenously and, after positioning it against the RV septum, driving it through the inter-ventricular septum into the LV endocardial layer.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of successful LV septum lead implantationsTime frame: Baseline and 6 months
  2. Change in sensing values, pacing threshold and lead impedanceTime frame: Baseline and 6 months
  3. Number of participants with procedure or lead related adverse eventsTime frame: Baseline and 6 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Maastricht University Medical Centre

    Maastricht, Limburg, Netherlands

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.